内源刺激响应药物输送纳米平台用于病治疗
Hufeng Fang1, Shan Xu1, Yu Wang1
1Department of Pharmacy, the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou 213100, China.
Colloids and surfaces. B, Biointerfaces
|October 22, 2023
概括
刺激响应纳米平台为脏疾病提供了一个有前途的治疗策略,克服了传统治疗方法的局限性. 这些先进的纳米材料提供精确的药物输送,有效地向患病的脏组织.
科学领域:
- 纳米医学和再生医学
- 生物技术和生物医学工程 生物技术和生物医学工程
背景情况:
- 脏疾病影响全球数百万人,目前的治疗方法如类固醇和免疫抑制剂会导致显著的全身毒性.
- 现有的疗法往往产生不理想的结果,需要创新的治疗策略.
研究的目的:
- 审查刺激响应药物输送纳米架构技术用于治疗脏疾病的最新进展.
- 探索内源刺激响应纳米材料在治疗病理方面的潜力.
主要方法:
- 根据病机制对内源性刺激 (pH,ROS,酶,葡萄糖) 的分类.
- 关于刺激反应的纳米材料的文献实例的总结.
- 这些纳米材料的设计策略和响应机制概述.
主要成果:
- 内源刺激响应的纳米平台显示了针对药物输送的增强的时空控制.
- 已经确定并分析了对特定病微环境做出反应的各种纳米材料.
- 这些先进的纳米药物的设计原理和作用机制得到了阐明.
结论:
- 响应刺激的纳米药物输送系统代表了病治疗的重大飞跃.
- 进一步的研究和开发对于克服当前挑战和加速临床转化至关重要.
- 这些纳米平台具有巨大的潜力,可以改善患者的治疗结果并减少与治疗相关的毒性.
相关概念视频
Drug Elimination by Renal Route: Tubular Secretion
2.4K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.4K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
19
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
19
Chronic Kidney Disease III: Interprofessional Care
21
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
21
Renal Drug Excretion: Tubular Reabsorption
193
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
193
Renal Drug Excretion: Tubular Secretion
196
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
196
Chronic Kidney Disease I: Introduction
18
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
18


